Janus Kinase (JAK) Inhibitors Market Size, Trends, Growth And Outlook By 2033

Overview and Scope

Janus Kinase (JAK) inhibitors are a class of drugs that block the activity of Janus Kinase enzymes. Janus Kinase (JAK) inhibitors are used for chronic inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, axial spondylarthritis, ulcerative colitis, atopic dermatitis, and alopecia areata.

 

Sizing and Forecast

The janus kinase (jak) inhibitors market size has grown rapidly in recent years. It will grow from $17.29 billion in 2023 to $20.41 billion in 2024 at a compound annual growth rate (CAGR) of 18.1%.  The growth in the historic period can be attributed to recognition of the role of jak-stat signaling pathway in diseases, increased prevalence of autoimmune disorders, unmet medical needs in rheumatology and dermatology, development of targeted therapies for inflammatory conditions, improvement in diagnostic capabilities for autoimmune diseases.

 

The janus kinase (jak) inhibitors market size is expected to see rapid growth in the next few years. It will grow to $39.92 billion in 2028 at a compound annual growth rate (CAGR) of 18.3%.  The growth in the forecast period can be attributed to growth of biopharmaceutical research and development, regulatory approvals for jak inhibitors in specific indications, expansion of clinical trials for jak inhibitor drugs, advances in personalized and precision medicine, adoption of jak inhibitors in combination therapies, integration of digital health technologies in autoimmune care. Major trends in the forecast period include focus on developing novel selective jak inhibitors for improved safety profiles, development of jak inhibitors with extended-release formulations, integration of artificial intelligence in jak inhibitor drug discovery, exploration of jak inhibitors in novel drug delivery systems, collaboration between pharmaceutical companies and research institutions.

 

To access more details regarding this report, visit the link:

https://www.thebusinessresearchcompany.com/report/janus-kinase-jak-inhibitors-global-market-report

 

Segmentation & Regional Insights

The janus kinase (jak) inhibitors market covered in this report is segmented –

1) By Inhibitors Type: Ruxolitinib, Tofacitinib, Oclacitinib, Baricitinib, Peficitinib, Other Inhibitor Types

2) By Mode Of Administration: Injectable, Oral, Other Modes Of Administration

3) By Distribution Channel: Hospital pharmacies, Retail pharmacies, Online pharmacies

4) By Application: Autoimmune Disorders, Oncology, Inflammatory Disorders, Metabolic Disorders

 

North America was the largest region in the Janus kinase (JAK) inhibitors market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the janus kinase (jak) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

 

Intrigued to explore the contents? Secure your hands-on sample copy of the report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12524&type=smp

 

Major Driver Impacting Market Growth

The increase in instances of autoimmune diseases is expected to propel the growth of the Janus kinase (JAK) inhibitors market. Autoimmune diseases are a broad group of disorders characterized by an abnormal immune response in which the immune system mistakenly attacks and damages healthy cells, tissues, and organs. Janus Kinase (JAK) inhibitors provide therapeutic benefits for autoimmune diseases by modulating the immune system, reducing inflammation, and alleviating symptoms such as rheumatoid arthritis. For instance, in December 2022, according to the National Psoriasis Foundation, a US-based non-profit organization serving people with Psoriasis and psoriatic arthritis, Psoriasis affected more than 8 million people in America and 125 million individuals worldwide, or 2 to 3% of the population. Furthermore, in September 2022, according to the Centers for Disease Control and Prevention, a US-based national public health agency, Diabetes was diagnosed in 28.7 million people of all ages, or 8.7% of the US population, and 5.7% of all US individuals with confirmed Diabetes—or 1.6 million people aged 20 and older—reported having type 1 diabetes and requiring insulin. Therefore, the increase in instances of autoimmune diseases is driving the growth of the Janus kinase (JAK) inhibitors market.

 

Key Industry Players

Major companies operating in the janus kinase (jak) inhibitors  market report are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi SA, Bristol Myers Squibb Co., GSK Plc., Takeda Pharmaceutical Company Ltd., Eli Lilly and Co., Gilead Sciences Inc., Boehringer Ingelheim Group, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., AstraZeneca PLC, Mitsubishi Tanabe Pharma Corporation, Incyte Corporation, Kyowa Hakko Kirin Co. Ltd., Galapagos NV, Sierra Oncology Inc., Dizal Pharmaceutical, Reistone Biopharma Co. Ltd., CTI BioPharma Corp., Celon Pharma SA, Theravance Biopharma Inc., Aclaris Therapeutics Inc., Alexion Pharmaceuticals Inc.

 

The janus kinase (jak) inhibitors market report table of contents includes:

1. Executive Summary
2. Janus Kinase (JAK) Inhibitors Market Characteristics
3. Janus Kinase (JAK) Inhibitors Market Trends And Strategies
4. Janus Kinase (JAK) Inhibitors Market – Macro Economic Scenario
5. Global Janus Kinase (JAK) Inhibitors Market Size and Growth
6. Janus Kinase (JAK) Inhibitors Market Segmentation
7. Janus Kinase (JAK) Inhibitors Market Regional And Country Analysis

………….

34. Key Mergers And Acquisitions In The Janus Kinase (JAK) Inhibitors Market
35. Janus Kinase (JAK) Inhibitors Market Future Outlook and Potential Analysis
36. Appendix

 

List Of Tables:

Table 1: Global Historic Market Growth, 2018-2023, $ Billion

Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion

Table 3: Global Janus Kinase (JAK) Inhibitors Market, Segmentation By Inhibitors Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 4: Global Janus Kinase (JAK) Inhibitors Market, Segmentation By Mode Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 5: Global Janus Kinase (JAK) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

……….

Table 75: Pfizer Inc. Financial Performance

Table 76: Merck & Co. Inc. Financial Performance

Table 77: AbbVie Inc. Financial Performance

Table 78: Novartis AG Financial Performance

Table 79: Sanofi SA Financial Performance

 

Explore the trending research reports from TBRC:

https://goodprnews.com/black-pepper-market-size/

https://topprnews.com/satellite-based-augmentation-system-market-overview/

 

Learn About Us:

The Business Research Company is a market intelligence firm that pioneers in market, company, and consumer research. TBRC’s specialist consultants are located globally and are experts in a wide range of industries that include healthcare, manufacturing, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

 

Contact Us:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info

 

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model